Full Fed. Circ. Limits On-Sale Bar's Reach In Angiomax Case

By Ryan Davis (July 11, 2016, 11:37 AM EDT) -- The full Federal Circuit ruled Monday that the on-sale bar invalidating a patent is triggered only by a transaction that "bears the general hallmarks of a sale," holding that The Medicines Co.'s deal with a supplier for experimental batches of the blood thinner Angiomax did not invalidate its patents.

In a unanimous en banc ruling, the full court reached the opposite conclusion from a panel decision last year that held that The Medicines Co.'s transaction was enough to render its patents on methods of making the drug invalid in a dispute with generics maker Hospira Inc.

The on-sale bar holds that...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!